Blumberg N, Laczin J, McMican A, Heal J, Arvan D
Transfusion. 1986 Nov-Dec;26(6):511-3. doi: 10.1046/j.1537-2995.1986.26687043615.x.
The use of 534 units of fresh-frozen plasma (FFP) during 160 transfusion episodes in 135 consecutive patients was reviewed. Only 27 percent of transfusions were indicated by a need for replacement of labile coagulation factors. Other uses included volume repletion (31%), intraoperative bleeding or massive transfusion without coagulopathy (19%), and miscellaneous indications unrelated to labile coagulation factors (23%). Data from other institutions and national sources support the hypothesis that much of the increase in FFP use over the last decade is related to decreases in whole blood availability rather than to use for labile coagulation factor replacement. The use of FFP and red cells as a substitute for, or in preference to, whole blood may have significant adverse implications in terms of the cost and safety of blood transfusion.
回顾了135例连续患者在160次输血过程中使用534单位新鲜冰冻血浆（FFP）的情况。只有27%的输血是因需要补充不稳定凝血因子而进行的。其他用途包括扩容（31%）、术中出血或无凝血病的大量输血（19%）以及与不稳定凝血因子无关的其他指征（23%）。来自其他机构和国家数据来源的数据支持这样一种假设，即过去十年中FFP使用量的大幅增加很大程度上与全血可获得性的下降有关，而非用于补充不稳定凝血因子。将FFP和红细胞作为全血的替代品或优先选择使用，可能在输血成本和安全性方面产生重大不利影响。
